Sandra Swain, MD Answers: Does This Data Reflect Our Everyday Practice? @SandraSwainMD @LombardiCancer #breastcancer #HER2

Sandra Swain, MD Answers: Does This Data Reflect Our Everyday Practice? @SandraSwainMD @LombardiCancer #breastcancer #HER2

Cancer-News

2 weeks
1 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer answers common questions in the phase 3 CLEOPATRA study in HER2 metastatic breast cancer. Does this data reflect our everyday practice?

____________

CLEOPATRA was a phase 3 trial comparing the efficacy and protection of pertuzumab, trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer with placebo, trastuzumab and docetaxel. In the primary study and subsequent studies, progression-free and overall survival in the pertuzumab group were substantially improved over placebo group. Here, we report CLEOPATRA's final-of-study review.

Read here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30863-0/fulltext

Up Next Autoplay